A new ai test has been developed to predict breast cancer recurrence using standard pathology slides. The test's capabilities and applications are still being explored, with some reports suggesting it can predict recurrence in a matter of hours and estimate the potential benefit of chemotherapy for individual patients. However, there is some uncertainty about the test's specific focus and scope, with one report mentioning its use for predicting meningioma recurrence rather than breast cancer.